Le point sur la scintigraphie osseuse dans les cancers urologiques de l'adulte

25 novembre 2008

Auteurs : D. Vilain, A. Hameg, C. Tainturier
Référence : Prog Urol, 2008, 18, S202, suppl. S7
   
 
 

 

 
Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser

   

 

 
 
 

Références

 

Cook G., Fogelman I. Radioisotope an PET imaging of Bone Metastases Textbook of Bone Metastasis West Sussex, England: Wiley (2005).  77-90
 
Sandler E.D., Parisi M.T., Hattner R.S. Duration of etidronate effect demonstrated by serial bone scintigraphy J Nucl Med 1991 ;  32 : 1782-1784
 
Hommeyer S.H., Varney D.M., Eary J.F. Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy J Nucl Med 1992 ;  33 : 748-750
 
Murphy K.J., Line B.R., Malfetano J. Etidrnate therapy decreases the sensitivity of bone scanning with methylene diphosphonate labelled with technetium-99m Can Assoc Radiol J 1997 ;  48 : 199-202
 
Soloway M.S., Hardeman S.W., Hickey D., Raymond J., Todd B., Soloway S., et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan Cancer 1988 ;  61 : 195-202 [cross-ref]
 
Noguchi M., Kikuchi H., Ishibashi M., Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer Br J Cancer 2003 ;  88 : 195-201 [cross-ref]
 
Yahara J., Noguchi M., Noda S. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment BJU Int 2003 ;  92 : 379-383 [cross-ref]
 
Strobel K., Burger C., Seifert B., Husarik D.B., Soyka J.D., Hany T.F. Characterization of focal bone lesions in the axial skeleton: performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT AJR Am J Roentgenol 2007 ;  188 : 467-474
 
Even-Sapir E., Metser U., Mishani E., Lievshitz G., Lerman H., Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT J Nucl Med 2006 ;  47 : 287-297
 
Utsunomiya D., Shiraishi S., Imuta M., Tomiguchi S., Kawanaka K., Morishita S., et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT Radiology 2006 ;  238 : 264-271 [cross-ref]
 
Even-Sapir E., Metser U., Flusser G., Zuriel L., Kollender Y., Lerman H., Lievshitz G., Ron I., Mishani E. Assessment of malignant skeletal disease:initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18Ffluoride PET/CT J Nucl Med 2004 ;  45 : 272-278
 
Abuzallouf S., Dayes I., Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature J Urol 2004 ;  171 : 2122-2127 [cross-ref]
 
Kosuda S., Yoshimura I., Aizawa T., Koizumi K., Akakura K., Kuyama J., et al. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan Cancer 2002 ;  94 : 964-972 [cross-ref]
 
Ishizuka O., Tanabe T., Nakayama T., Kawakami M., Kinebuchi Y., Nishizawa O. Prostate-specific antigen. Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan Int J Urol 2005 ;  12 : 728-732 [cross-ref]
 
Soulié M., Beuzeboc P., Cornud F., Eschwege P., Gaschignard N., Grosclaude P., et al. Comité de Cancérologie de l’Association Française d’Urologie. Prostate Cancer Prog Urol 2007 ;  17 : 1159-1230
 
Méjean A., André M., Doublet J.D., Fendler J.P., de Fromont M., Hélénon O., et al. Comité de Cancérologie de l’Association Française d’Urologie:Kidney tumors Prog Urol 2004 ;  14 : 999-1035997.
 
Koga S., Tsuda S., Nishikido M., Ogawa Y., Hayashi K., Hayashi T., et al. The diagnostic value of bone scan in patients with renal cell carcinoma J Urol 2001 ;  166 : 2126-2128 [cross-ref]
 
Shvarts O., Lam J.S., Kim H.L., Han K.R., Figlin R., Belldegrun A. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans J Urol 2004 ;  172 : 867-870 [cross-ref]
 
Comité de Cancérologie de l’Association Française d’Urologie. Prostate Cancer. Prog Urol 2007; 17:1035-1158.
 
   
 
 
   

 

© 2008  Elsevier Masson SAS. Tous droits réservés.